Journal of the American Chemical Society,
Journal Year:
2024,
Volume and Issue:
146(42), P. 28783 - 28794
Published: Oct. 11, 2024
Currently
used
drugs
for
glioblastoma
(GBM)
treatments
are
ineffective,
primarily
due
to
the
significant
challenges
posed
by
strong
drug
resistance,
poor
blood-brain
barrier
(BBB)
permeability,
and
lack
of
tumor
specificity.
Here,
we
report
two
cationic
fluorescent
anticancer
agents
(TriPEX-ClO
Journal of the American Chemical Society,
Journal Year:
2022,
Volume and Issue:
144(32), P. 14420 - 14440
Published: Aug. 4, 2022
There
has
been
emerging
interest
in
the
exploitation
of
photophysical
and
photochemical
properties
transition
metal
complexes
for
diagnostic
therapeutic
applications.
In
this
Perspective,
we
highlight
major
recent
advances
development
luminescent
photofunctional
complexes,
particular,
those
rhenium(I),
ruthenium(II),
osmium(II),
iridium(III),
platinum(II),
as
bioimaging
reagents
phototherapeutic
agents,
with
a
focus
on
molecular
design
strategies
that
harness
modulate
interesting
behavior
complexes.
We
also
discuss
current
challenges
future
outlook
both
fundamental
research
clinical
Chemical Science,
Journal Year:
2022,
Volume and Issue:
13(18), P. 5085 - 5106
Published: Jan. 1, 2022
This
minireview
summarizes
recent
developments
of
noble
metal
photosensitizers
based
on
Ru,
Ir,
and
Pt.
Molecular
design
strategies
to
overcome
shallow
tissue
penetration
depth,
O
2
-dependence
the
limited
therapeutic
effect
are
introduced.
Chemical Society Reviews,
Journal Year:
2023,
Volume and Issue:
52(13), P. 4392 - 4442
Published: Jan. 1, 2023
Metal
agents
have
made
incredible
strides
in
preclinical
research
and
clinical
applications,
but
their
short
emission/absorption
wavelengths
continue
to
be
a
barrier
distribution,
therapeutic
action,
visual
tracking,
efficacy
evaluation.
Angewandte Chemie International Edition,
Journal Year:
2023,
Volume and Issue:
62(24)
Published: March 9, 2023
Conventional
photocages
only
respond
to
short
wavelength
light,
which
is
a
significant
obstacle
developing
efficient
phototherapy
in
vivo.
The
development
of
activated
by
near-infrared
(NIR)
light
at
wavelengths
from
700
950
nm
important
for
vivo
studies
but
remains
challenging.
Herein,
we
describe
the
synthesis
photocage
based
on
ruthenium
(Ru)
complex
with
NIR
light-triggered
photocleavage
reaction.
commercial
anticancer
drug,
tetrahydrocurcumin
(THC),
was
coordinated
RuII
center
create
Ru-based
that
readily
responsive
760
nm.
inherited
properties
THC.
As
proof-of-concept,
further
engineered
self-assembled
photocage-based
nanoparticle
system
amphiphilic
block
copolymers.
Upon
exposure
nm,
Ru
complex-based
were
released
polymeric
nanoparticles
and
efficiently
inhibited
tumor
proliferation
Advanced Functional Materials,
Journal Year:
2023,
Volume and Issue:
33(25)
Published: March 10, 2023
Abstract
As
a
less
O
2
‐dependent
photodynamic
therapy
(PDT),
type
I
PDT
is
an
effective
approach
to
overcome
the
hypoxia‐induced
low
efficiency
against
solid
tumors.
However,
commonly
used
metal‐involved
agents
suffer
from
long‐term
biosafety
concern.
Herein,
metal‐free
photosensitizer,
N
‐doped
carbon
dots/mesoporous
silica
nanoparticles
(NCDs/MSN,
≈40
nm)
nanohybrid
with
peroxidase
(POD)‐like
activity
for
synergistic
and
enzyme‐activity
treatment,
developed
on
gram
scale
via
facile
one‐pot
strategy
through
mixing
source
precursor
assistance
of
template.
Benefiting
narrow
bandgap
(1.92
eV)
good
charge
separation
capacity
NCDs/MSN,
upon
640
nm
light
irradiation,
excited
electrons
in
conduction
band
can
effectively
generate
•−
by
reduction
dissolved
one‐electron
transfer
process
even
under
hypoxic
conditions,
inducing
apoptosis
tumor
cells.
Moreover,
photoinduced
partially
transform
into
more
toxic
•
OH
two‐electron
reduction.
POD‐like
NCDs/MSN
catalyze
endogenous
H
microenvironment,
further
synergistically
ablating
4T1
Therefore,
mass
production
way
synthesize
novel
photosensitizer
enzyme‐mimic
treatment
tumors
provided,
which
exhibits
promising
clinical
translation
prospects.
Angewandte Chemie International Edition,
Journal Year:
2023,
Volume and Issue:
62(43)
Published: Sept. 5, 2023
Despite
metal-based
photosensitizers
showing
great
potential
in
photodynamic
therapy
for
tumor
treatment,
the
application
of
is
intrinsically
limited
by
their
poor
cancer-targeting
properties.
Herein,
we
reported
a
photosensitizer-bacteria
hybrid,
Ir-HEcN,
via
covalent
labeling
an
iridium(III)
photosensitizer
to
surface
genetically
engineered
bacteria.
Due
its
intrinsic
self-propelled
motility
and
hypoxia
tropism,
Ir-HEcN
selectively
targets
penetrates
deeply
into
tissues.
Importantly,
capable
inducing
pyroptosis
immunogenic
cell
death
cells
under
irradiation,
thereby
remarkably
evoking
anti-tumor
innate
adaptive
immune
responses
vivo
leading
regression
solid
tumors
combinational
immunotherapy.
To
best
our
knowledge,
first
metal
complex
decorated
bacteria
enhanced
Nature Communications,
Journal Year:
2024,
Volume and Issue:
15(1)
Published: Jan. 2, 2024
Abstract
Practical
photodynamic
therapy
calls
for
high-performance,
less
O
2
-dependent,
long-wavelength-light-activated
photosensitizers
to
suit
the
hypoxic
tumor
microenvironment.
Iridium-based
exhibit
excellent
photocatalytic
performance,
but
in
vivo
applications
are
hindered
by
conventional
-dependent
Type-II
photochemistry
and
poor
absorption.
Here
we
show
a
general
metallopolymerization
strategy
engineering
iridium
complexes
exhibiting
Type-I
enhancing
absorption
intensity
blue
near-infrared
region.
Reactive
oxygen
species
generation
of
metallopolymer
Ir-P1
,
where
atom
is
covalently
coupled
polymer
backbone,
over
80
times
higher
than
that
its
mother
without
under
680
nm
irradiation.
This
also
works
effectively
when
directly
included
(
Ir-P2
)
backbones,
wide
generality.
The
nanoparticles
efficient
•−
conjugated
with
integrin
αvβ3
binding
cRGD
achieve
targeted
therapy.
Aggregate,
Journal Year:
2024,
Volume and Issue:
unknown
Published: March 24, 2024
Abstract
Currently
three
major
problems
seriously
limit
the
practical
application
of
cancer
photodynamic
therapy
(PDT):
(i)
hypoxic
tumor
microenvironment
(TME);
(ii)
low
generation
efficiency
toxic
reactive
oxygen
species
(ROS)
in
aggregates
and
(iii)
shallow
tissue
penetration
depth
excitation
light.
Very
limited
approaches
are
available
for
addressing
all
above
with
a
single
design.
Herein,
rational
“three
birds
one
stone”
molecular
nanoengineering
strategy
is
demonstrated:
nanoplatform
U‐Ir@PAA‐ABS
based
on
covalent
combination
lanthanide‐doped
upconversion
nanoparticles
(UCNPs)
an
AIE‐active
dinuclear
Ir(III)
complex
provides
concentration‐dependent
type‐I
photochemical
process
upon
980
nm
irradiation
by
Föster
resonance
energy
transfer
(FRET).
targets
mitochondria
has
excellent
phototoxicity
even
severe
hypoxia
environments
irradiation,
inducing
dual‐mode
cell
death
mechanism
apoptosis
ferroptosis.
Taken
together,
vitro
vivo
results
demonstrate
successful
improving
efficacy
PDT
against
tumors.